Αποτελέσματα Αναζήτησης
15 Ιαν 2024 · People who have interstitial lung disease along with systemic sclerosis are much more likely to die from disease complications than people who do not have lung disease. Around 80% to 90% are alive five years after being diagnosed with interstitial lung disease from systemic sclerosis.
22 Μαΐ 2020 · Despite improved survival, the number one cause of death for most systemic sclerosis–associated interstitial lung disease patients remains respiratory failure from interstitial lung disease.
15 Ιουλ 2017 · The 5-year mortality for patients with progressive systemic sclerosis and ILD have a survival of 82–90% in 5 years, with ILD or pulmonary hypertension being responsible for 60% of the mortality observed in such cases [5].
Similarly, the prognostic value of lung biopsy in patients with SSc-associated ILD is of limited value whereas assessment of clinical severity and lung function impairment are better predictors of outcome.
2 Ιαν 2024 · The spectrum of pulmonary complications of SSc and an approach to their evaluation will be reviewed here. The clinical manifestations, diagnosis, therapy, and prognosis of SSc-associated ILD and PAH are discussed separately.
Pulmonary involvement in systemic sclerosis In scleroderma, the two most common types of direct pulmonary involvement are ILD and PH, which together account for 60% of SSc-related deaths [2].
27 Νοε 2021 · Diagnosis of ILD in SSc. The onset of ILD in scleroderma is often difficult to detect. Factors that may mask the onset of disease include mild lung involvement, musculoskeletal, or hematologic (such as anemia) manifestations of SSc or other comorbid conditions.
